Correction: Evaluating the Safety and Efficacy of Varenicline for Smoking Cessation in Patients With Schizophrenia

Letter to the Editor

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

In the article “A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Varenicline for Smoking Cessation in Patients With Schizophrenia or Schizoaffective Disorder” by Jill M. Williams, MD, and colleagues published in the May 2012 issue (J Clin Psychiatry 2012;73[5]:654-660), the percentage of 52/84 patients on page 658 should be 61.9%. The online article at PSYCHIATRIST.COM has been corrected.